avasimibe has been researched along with Hyperlipemia in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (80.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
de Voogd, NJ; Eguchi, K; Fujiwara, Y; Hayashida, A; Horlad, H; Kato, H; Losung, F; Mangindaan, RE; Rotinsulu, H; Takeya, M; Tsukamoto, S | 1 |
Burnett, JR; Huff, MW | 1 |
Alegret, M; Laguna, JC; LlaverÃas, G | 1 |
Badimon, JJ; Chew, DP; Corti, R; Fallon, JT; Fayad, ZA; Fuster, V; Helft, G; Worthley, MI; Worthley, SG; Zaman, AG | 1 |
3 review(s) available for avasimibe and Hyperlipemia
Article | Year |
---|---|
Avasimibe Pfizer.
Topics: Acetamides; Acetates; Animals; Arteriosclerosis; Clinical Trials as Topic; Drug Industry; Enzyme Inhibitors; Humans; Hyperlipidemias; Sulfonamides; Sulfonic Acids | 2002 |
Pharmacology of the ACAT inhibitor avasimibe (CI-1011).
Topics: Acetamides; Acetates; Animals; Anticholesteremic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hyperlipidemias; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2003 |
Avasimibe. CI 1011.
Topics: Acetamides; Acetates; Animals; Clinical Trials as Topic; Drug Industry; Humans; Hyperlipidemias; Sulfonamides; Sulfonic Acids | 2002 |
2 other study(ies) available for avasimibe and Hyperlipemia
Article | Year |
---|---|
Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
Topics: Alkaloids; Animals; Atherosclerosis; Carbazoles; Cells, Cultured; CHO Cells; Cholesterol; Cholesterol Esters; Cricetinae; Cricetulus; Foam Cells; Humans; Hyperlipidemias; Lipoproteins, LDL; Macrophages; Mice; Mice, Inbred C57BL; Porifera; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2 | 2013 |
Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
Topics: Acetamides; Acetates; Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Catheterization; Cholesterol; Disease Progression; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Magnetic Resonance Imaging; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Pyrroles; Rabbits; Random Allocation; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2007 |